Effects of thiazides and new findings on kidney stones and dysglycemic side effects.

diabetes mellitus glucose intolerance kidney stone nephrolithiasis thiazide

Journal

Acta physiologica (Oxford, England)

ISSN: 1748-1716

Titre abrégé: Acta Physiol (Oxf)

Pays: England

ID NLM: 101262545

Informations de publication

Date de publication:
03 May 2024

Historique:

revised: 08 04 2024

received: 22 02 2024

accepted: 22 04 2024

medline: 3 5 2024

pubmed: 3 5 2024

entrez: 3 5 2024

Statut: aheadofprint

Résumé

Thiazide and thiazide-like diuretics (thiazides) belong to the most frequently prescribed drugs worldwide. By virtue of their natriuretic and vasodilating properties, thiazides effectively lower blood pressure and prevent adverse cardiovascular outcomes. In addition, through their unique characteristic of reducing urine calcium, thiazides are also widely employed for the prevention of kidney stone recurrence and reduction of bone fracture risk. Since their introduction into clinical medicine in the early 1960s, thiazides have been recognized for their association with metabolic side effects, particularly impaired glucose tolerance, and new-onset diabetes mellitus. Numerous hypotheses have been advanced to explain thiazide-induced glucose intolerance, yet underlying mechanisms remain poorly defined. Regrettably, the lack of understanding and unpredictability of these side effects has prompted numerous physicians to refrain from prescribing these effective, inexpensive, and widely accessible drugs. In this review, we outline the pharmacology and mechanism of action of thiazides, highlight recent advances in the understanding of thiazide-induced glucose intolerance, and provide an up-to-date discussion on the role of thiazides in kidney stone prevention.

Identifiants

DOI: 10.1111/apha.14155 PMID: 38698738

pubmed: 38698738

doi: 10.1111/apha.14155

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Pagination

e14155

Subventions

Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Organisme : Swiss National Centre of Competence in Research Kidney Control of Homeostasis

Organisme : Inselspital, Universitätsspital Bern

Organisme : Novartis Foundation for Medical-Biological Research

Informations de copyright

Références

Bhadoriya SS, Ganeshpurkar A, Narwaria J, Rai G, Jain AP. Tamarindus indica: extent of explored potential. Pharmacogn Rev. 2011;5(9):73‐81.

Riddle JM. One Plant, One Chapter. In: Dioscorides on Pharmacy and Medicine. New York, USA: University of Texas Press; 1985. p.25‐93. https://doi.org/10.7560/715448‐005

Ebers G, Stern L. Papyros Ebers: das Hermetische Buch über die Arzneimittel der alten Ägypter in hieratischer Schrift. 1875.

Totelin L. Hippocratic Recipes: Oral and Written Transmission of Pharmacological Knowledge in Fifth‐and Fourth‐Century Greece. Hippocratic Recipes. Brill; 2008.

Eknoyan G. A history of edema and its management. Kidney Int Suppl. 1997;59:S118‐S126.

Stringham JS. On the diuretic effects of mercury in a case of syphilis. Med Phys J. 1807;18(104):331‐333.

Mann T, Keilin D. Sulphanilamide as a specific inhibitor of carbonic anhydrase. Nature. 1940;146(3692):164‐165.

Southworth H, Long PH, White F. Acidosis associated with the administration of para‐amino‐benzene‐sulfonamide (Prontylin). Proc Soc Exp Biol Med. 1937;36(1):58‐61.

Strauss MB, Southworth H. Urinary changes due to sulfanilamide administration. Bull Johns Hopkins Hosp. 1938;63:41.

Moser M, Feig PU. Fifty years of thiazide diuretic therapy for hypertension. Arch Intern Med. 2009;169(20):1851‐1856.

Roblin RO, Clapp JW. The preparation of heterocyclic sulfonamides1. J Am Chem Soc. 1950;72:4890‐4892.

Hanley T, Platts MM. Acetazolamide (diamox) in the treatment of congestive heart‐failure. Lancet. 1956;267(6919):357‐359.

Counihan TB, Evans BM, Milne MD. Observations on the pharmacology of the carbonic anhydrase inhibitor diamox. Clin Sci. 1954;13(4):583‐598.

Novello FC, Sprague JM. Benzothiadiazine dioxides as novel diuretics. J Am Chem Soc. 1957;79:2028‐2029.

Beyer KH. The mechanism of action of chlorothiazide. Ann N Y Acad Sci. 1958;71(4):363‐379.

Beyer KH Jr, Baer JE, Russo HF, Noll R. Electrolyte excretion as influenced by chlorothiazide. Science. 1958;127(3290):146‐147.

Reilly RF, Peixoto AJ, Desir GV. The evidence‐based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol. 2010;5(10):1893‐1903.

James PA, Oparil S, Carter BL, et al. 2014 evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507‐520.

Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981‐2997.

Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002;288(23):3039‐3042.

Lamberg BA, Kuhlback B. Effect of chlorothiazide and hydrochlorothiazide on the excretion of calcium in urine. Scand J Clin Lab Invest. 1959;11:351‐357.

Lichtwitz A, Parlier R, Hioco D, Miravet L. The hypocalciuric effect of diuretic sulfonamides. Sem Med Prof Med Soc. 1961;37:2350‐2362.

Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med. 2013;158(7):535‐543.

Li DF, Gao YL, Liu HC, Huang XC, Zhu RF, Zhu CT. Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta‐analysis. J Transl Med. 2020;18(1):106.

Dhayat NA, Bonny O, Roth B, et al. Hydrochlorothiazide and prevention of kidney‐stone recurrence. N Engl J Med. 2023;388(9):781‐791.

Duarte JD, Cooper‐DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide‐like diuretics. Expert Rev Cardiovasc Ther. 2010;8(6):793‐802.

Simon DB, Nelson‐Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide‐sensitive Na‐Cl cotransporter. Nat Genet. 1996;12(1):24‐30.

Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide‐induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005;115(6):1651‐1658.

Gesek FA, Friedman PA. Mechanism of calcium transport stimulated by chlorothiazide in mouse distal convoluted tubule cells. J Clin Invest. 1992;90(2):429‐438.

Fan M, Zhang J, Lee CL, Zhang J, Feng L. Structure and thiazide inhibition mechanism of the human Na‐Cl cotransporter. Nature. 2023;614(7949):788‐793.

Beaumont K, Vaughn DA, Fanestil DD. Thiazide diuretic drug receptors in rat kidney: identification with [3H]metolazone. Proc Natl Acad Sci USA. 1988;85(7):2311‐2314.

Schultheis PJ, Lorenz JN, Meneton P, et al. Phenotype resembling Gitelman's syndrome in mice lacking the apical Na+‐Cl− cotransporter of the distal convoluted tubule. J Biol Chem. 1998;273(44):29150‐29155.

Loffing J, Vallon V, Loffing‐Cueni D, et al. Altered renal distal tubule structure and renal Na(+) and Ca(2+) handling in a mouse model for Gitelman's syndrome. J Am Soc Nephrol. 2004;15(9):2276‐2288.

Morris RG, Hoorn EJ, Knepper MA. Hypokalemia in a mouse model of Gitelman's syndrome. Am J Physiol Renal Physiol. 2006;290(6):F1416‐F1420.

Temperini C, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase activators: kinetic and X‐ray crystallographic study for the interaction of D‐ and L‐tryptophan with the mammalian isoforms I–XIV. Bioorg Med Chem. 2008;16(18):8373‐8378.

Bua S, Nocentini A, Supuran CT. Chapter 14—carbonic anhydrase inhibitors as diuretics. In: Supuran CT, Nocentini A, eds. Carbonic Anhydrases. Academic Press; 2019:287‐309.

Pickkers P, Garcha RS, Schachter M, Smits P, Hughes AD. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Hypertension. 1999;33(4):1043‐1048.

Kunau RT Jr, Weller DR, Webb HL. Clarification of the site of action of chlorothiazide in the rat nephron. J Clin Invest. 1975;56(2):401‐407.

Leviel F, Hubner CA, Houillier P, et al. The Na+−dependent chloride‐bicarbonate exchanger SLC4A8 mediates an electroneutral Na+ reabsorption process in the renal cortical collecting ducts of mice. J Clin Invest. 2010;120(5):1627‐1635.

Eladari D, Hubner CA. Novel mechanisms for NaCl reabsorption in the collecting duct. Curr Opin Nephrol Hypertens. 2011;20(5):506‐511.

Xu J, Barone S, Zahedi K, Brooks M, Soleimani M. Slc4a8 in the kidney: expression, subcellular localization and role in salt reabsorption. Cell Physiol Biochem. 2018;50(4):1361‐1375.

Sinning A, Radionov N, Trepiccione F, et al. Double knockout of the Na+‐driven Cl−/HCO3− exchanger and Na+/Cl− cotransporter induces hypokalemia and volume depletion. J Am Soc Nephrol. 2017;28(1):130‐139.

Royaux IE, Wall SM, Karniski LP, et al. Pendrin, encoded by the Pendred syndrome gene, resides in the apical region of renal intercalated cells and mediates bicarbonate secretion. Proc Natl Acad Sci USA. 2001;98(7):4221‐4226.

Wall SM, Kim YH, Stanley L, et al. NaCl restriction upregulates renal Slc26a4 through subcellular redistribution: role in Cl− conservation. Hypertension. 2004;44(6):982‐987.

Soleimani M, Barone S, Xu J, et al. Double knockout of pendrin and Na‐Cl cotransporter (NCC) causes severe salt wasting, volume depletion, and renal failure. Proc Natl Acad Sci USA. 2012;109(33):13368‐13373.

Makam AN, Boscardin WJ, Miao Y, Steinman MA. Risk of thiazide‐induced metabolic adverse events in older adults. J Am Geriatr Soc. 2014;62(6):1039‐1045.

Sharabi Y, Illan R, Kamari Y, et al. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens. 2002;16(9):631‐635.

Lin Z, Wong LYF, Cheung BMY. Diuretic‐induced hypokalaemia: an updated review. Postgrad Med J. 2022;98(1160):477‐482.

Ware JS, Wain LV, Channavajjhala SK, et al. Phenotypic and pharmacogenetic evaluation of patients with thiazide‐induced hyponatremia. J Clin Invest. 2017;127(9):3367‐3374.

Liamis G, Filippatos TD, Elisaf MS. Thiazide‐associated hyponatremia in the elderly: what the clinician needs to know. J Geriatr Cardiol. 2016;13(2):175‐182.

Ashraf N, Locksley R, Arieff AI. Thiazide‐induced hyponatremia associated with death or neurologic damage in outpatients. Am J Med. 1981;70(6):1163‐1168.

Cesar KR, Magaldi AJ. Thiazide induces water absorption in the inner medullary collecting duct of normal and Brattleboro rats. Am J Phys. 1999;277(5):F756‐F760.

Clark BA, Shannon RP, Rosa RM, Epstein FH. Increased susceptibility to thiazide‐induced hyponatremia in the elderly. J Am Soc Nephrol. 1994;5(4):1106‐1111.

Hoorn EJ, Wetzels JFM. Prostaglandins in thiazide‐induced hyponatraemia: do they hold water? Nat Rev Nephrol. 2017;13(11):665‐666.

Earley LE, Orloff J. The mechanism of antidiuresis associated with the administration of hydrochlorothiazide to patients with vasopressin‐resistant diabetes insipidus. J Clin Invest. 1962;41(11):1988‐1997.

Kim GH, Lee JW, Oh YK, et al. Antidiuretic effect of hydrochlorothiazide in lithium‐induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin‐2, Na‐Cl co‐transporter, and epithelial sodium channel. J Am Soc Nephrol. 2004;15(11):2836‐2843.

Sinke AP, Kortenoeven ML, de Groot T, et al. Hydrochlorothiazide attenuates lithium‐induced nephrogenic diabetes insipidus independently of the sodium‐chloride cotransporter. Am J Physiol Renal Physiol. 2014;306(5):F525‐F533.

Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation. 1959;20:1028‐1036.

Bennett WM, McDonald WJ, Kuehnel E, Hartnett MN, Porter GA. Commentary. Clin Pharmacol Ther. 1977;22(5part1):499‐504.

Tarazi RC, Dustan HP, Frohlich ED. Long‐term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation. 1970;41(4):709‐717.

Priddle WW, Liu SF, Breithaupt DJ. Management of hypertension—further sodium and potassium studies. J Am Geriatr Soc. 1970;18(11):861‐892.

Hughes AD. How do thiazide and thiazide‐like diuretics lower blood pressure? J Renin‐Angio‐Aldo Syst. 2004;5(4):155‐160.

Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide‐like diuretics. Expert Opin Pharmacother. 2014;15(4):527‐547.

Calder JA, Schachter M, Sever PS. Potassium channel opening properties of thiazide diuretics in isolated Guinea pig resistance arteries. J Cardiovasc Pharmacol. 1994;24(1):158‐164.

Colas B, Slama M, Collin T, Safar M, Andrejak M. Mechanisms of methyclothiazide‐induced inhibition of contractile responses in rat aorta. Eur J Pharmacol. 2000;408(1):63‐67.

Zhu Z, Zhu S, Liu D, Cao T, Wang L, Tepel M. Thiazide‐like diuretics attenuate agonist‐induced vasoconstriction by calcium desensitization linked to rho kinase. Hypertension. 2005;45(2):233‐239.

Calder JA, Schachter M, Sever PS. Ion channel involvement in the acute vascular effects of thiazide diuretics and related compounds. J Pharmacol Exp Ther. 1993;265(3):1175‐1180.

De Wildt DJ, Van de Kuil A, Hillen FC, De Groot G. Further study of possible direct vascular actions of indapamide in the conduit and renal arteriolar vessels of spontaneously hypertensive rats. Eur J Pharmacol. 1988;147(3):327‐334.

Del Rio M, Chulia T, Gonzalez P, Tejerina T. Effects of indapamide on contractile responses and 45Ca2+ movements in various isolated blood vessels. Eur J Pharmacol. 1993;250(1):133‐139.

Mironneau J, Savineau JP, Mironneau C. Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. Eur J Pharmacol. 1981;75(2–3):109‐113.

Rapoport RM, Soleimani M. Mechanism of thiazide diuretic arterial pressure reduction: the search continues. Front Pharmacol. 2019;10:815.

Pickkers P, Hughes AD, Russel FG, Thien T, Smits P. Thiazide‐induced vasodilation in humans is mediated by potassium channel activation. Hypertension. 1998;32(6):1071‐1076.

Overbeck HW, Molnar JI, Haddy FJ. Resistance to blood flow through the vascular bed of the dog forelimb: local effects of sodium, potassium, calcium, magnesium, acetate, hypertonicity and hypotonicity. Am J Cardiol. 1961;8(4):533‐541.

Swenson ER. New insights into carbonic anhydrase inhibition, vasodilation, and treatment of hypertensive‐related diseases. Curr Hypertens Rep. 2014;16(9):467.

Scales CD Jr, Smith AC, Hanley JM, Saigal CS. Urologic diseases in America P. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160‐165.

Coe FL, Worcester EM, Evan AP. Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol. 2016;12(9):519‐533.

Kirkali Z, Rasooly R, Star RA, Rodgers GP. Urinary stone disease: Progress, status, and needs. Urology. 2015;86(4):651‐653.

Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):120‐132.

Asplin J, Parks J, Lingeman J, et al. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol. 1998;159(6):1821‐1825.

Parks JH, Coward M, Coe FL. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 1997;51(3):894‐900.

Coe FL, Wise H, Parks JH, Asplin JR. Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol. 2001;166(4):1247‐1251.

Rodgers A, Allie‐Hamdulay S, Jackson G. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant. 2006;21(2):361‐369.

Marangella M, Petrarulo M, Vitale C, Daniele P, Sammartano S. LITHORISK.COM: the novel version of a software for calculating and visualizing the risk of renal stone. Urolithiasis. 2021;49(3):211‐217.

Werness PG, Brown CM, Smith LH, Finlayson B. EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol. 1985;134(6):1242‐1244.

Ferraro PM, Ticinesi A, Meschi T, et al. Short‐term changes in urinary relative supersaturation predict recurrence of kidney stones: a tool to guide preventive measures in urolithiasis. J Urol. 2018;200(5):1082‐1087.

Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5‐year randomized prospective study. J Urol. 1996;155(3):839‐843.

Prochaska M, Taylor E, Ferraro PM, Curhan G. Relative supersaturation of 24‐hour urine and likelihood of kidney stones. J Urol. 2018;199(5):1262‐1266.

Rodriguez A, Cunha TDS, Rodgers AL, Gambaro G, Ferraro PM. Comparison of supersaturation outputs from different programs and their application in testing correspondence with kidney stone composition. J Endourol. 2021;35(5):687‐694.

Siener R, Glatz S, Nicolay C, Hesse A. Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients. Eur Urol. 2003;44(4):467‐474.

Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346(2):77‐84.

Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367(9507):333‐344.

Taylor EN, Curhan GC. Demographic, dietary, and urinary factors and 24‐h urinary calcium excretion. Clin J Am Soc Nephrol. 2009;4(12):1980‐1987.

Curhan GC, Taylor EN. 24‐h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489‐496.

Arivoli K, Valicevic AN, Oerline MK, et al. Preventive Pharmacological Therapy and Risk of Recurrent Urinary Stone Disease. Clin J Am Soc Nephrol. 2024;9900:1‐8. doi:10.2215/CJN.0000000000000428. Epub ahead of print.

Bergsland KJ, Worcester EM, Coe FL. Role of proximal tubule in the hypocalciuric response to thiazide of patients with idiopathic hypercalciuria. Am J Physiol Renal Physiol. 2013;305(4):F592‐F599.

Costanzo LS, Windhager EE. Calcium and sodium transport by the distal convoluted tubule of the rat. Am J Phys. 1978;235(5):F492‐F506.

Lee CT, Shang S, Lai LW, Yong KC, Lien YH. Effect of thiazide on renal gene expression of apical calcium channels and calbindins. Am J Physiol Renal Physiol. 2004;287(6):F1164‐F1170.

Lee J, Cha S‐K, Sun T‐J, Huang C‐L. PIP2 activates TRPV5 and releases its inhibition by intracellular Mg2+. J General Physiol. 2005;126(5):439‐451.

Rodenburg EM, Visser LE, Hoorn EJ, et al. Thiazides and the risk of hypokalemia in the general population. J Hypertens. 2014;32(10):2092‐2097. discussion 2097.

Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219‐224.

Liamis G, Rodenburg EM, Hofman A, Zietse R, Stricker BH, Hoorn EJ. Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med. 2013;126(3):256‐263.

Pak CY, Peterson R, Sakhaee K, Fuller C, Preminger G, Reisch J. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide‐unresponsive hypercalciuric nephrolithiasis. Am J Med. 1985;79(3):284‐288.

Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009;11(3):134‐144.

Ellison DH, Loffing J. Thiazide effects and adverse effects: insights from molecular genetics. Hypertension. 2009;54(2):196‐202.

Adler S, Fraley DS. Potassium and intracellular pH. Kidney Int. 1977;11(6):433‐442.

Soleimani M, Bergman JA, Hosford MA, McKinney TD. Potassium depletion increases luminal Na+/H+ exchange and basolateral Na+:CO3=:HCO3− cotransport in rat renal cortex. J Clin Invest. 1990;86(4):1076‐1083.

Levi M, McDonald LA, Preisig PA, Alpern RJ. Chronic K depletion stimulates rat renal brush‐border membrane Na‐citrate cotransporter. Am J Phys. 1991;261(5 Pt 2):F767‐F773.

Moe OW, Preisig PA. Dual role of citrate in mammalian urine. Curr Opin Nephrol Hypertens. 2006;15(4):419‐424.

Scholz D, Schwille PO, Sigel A. Double‐blind study with thiazide in recurrent calcium lithiasis. J Urol. 1982;128(5):903‐907.

Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol. 1993;22(Suppl 6):S78‐S86.

Triozzi JL, Hsi RS, Wang G, et al. Mendelian randomization analysis of genetic proxies of thiazide diuretics and the reduction of kidney stone risk. JAMA Netw Open. 2023;6(11):e2343290.

Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol. 1988;139(4):679‐684.

Lemieux G. Treatment of idiopathic hypercalciuria with indapamide. CMAJ. 1986;135(2):119‐121.

Borghi L, Elia G, Trapassi MR, et al. Acute effect of indapamide on urine calcium excretion in nephrolithiasis and human essential hypertension. Pharmacology. 1988;36(5):348‐355.

Wolfgram DF, Gundu V, Astor BC, Jhagroo RA. Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones. Urolithiasis. 2013;41(4):315‐322.

Coe FL, Parks JH, Bushinsky DA, Langman CB, Favus MJ. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988;33(6):1140‐1146. doi: 10.1038/ki.1988

Martins MC, Meyers AM, Whalley NA, Margolius LP, Buys ME. Indapamide (Natrilix): the agent of choice in the treatment of recurrent renal calculi associated with idiopathic hypercalciuria. Br J Urol. 1996;78(2):176‐180.

Alonso D, Pieras E, Piza P, Grases F, Prieto RM. Effects of short and long‐term indapamide treatments on urinary calcium excretion in patients with calcium oxalate dihydrate urinary stone disease: a pilot study. Scand J Urol Nephrol. 2012;46(2):97‐101.

Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double‐blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. 1993;150(6):1761‐1764.

Ettinger B, Pak CY, Citron JT, Thomas C, Adams‐Huet B, Vangessel A. Potassium‐magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997;158(6):2069‐2073.

Phillips R, Hanchanale VS, Myatt A, Somani B, Nabi G, Biyani CS. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev. 2015;2015(10):CD010057.

Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316‐324.

Ljungberg B, Albiges L, Bedke J, et al. EAU guidelines, edn. Presented at the EAU Annual Congress Milan 2021. EAU Guidelines Office; 2021 http://uroweborg/guidelines/compilations‐of‐all‐guidelines

Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD. Clinical Guidelines Committee of the American College of Physicians. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(9):659‐667. doi: 10.7326/M13-2908

Amery A, Berthaux P, Bulpitt C, et al. Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. Lancet. 1978;1(8066):681‐683.

Goldner MG, Zarowitz H, Akgun S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N Engl J Med. 1960;262:403‐405.

Hollis WC. Aggravation of diabetes mellitus during treatment with chlorothiazide. JAMA. 1961;176:947‐949.

Samaan N, Dollery CT, Fraser R. Diabetogenic action of benzothiadiazines: serum‐insulin‐like activity in diabetes worsened or precipitated by thiazide diuretics. Lancet. 1963;2(7320):1244‐1246.

Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care. 2006;29(5):1065‐1070.

Bengtsson C, Blohme G, Lapidus L, et al. Do antihypertensive drugs precipitate diabetes? Br Med J (Clin Res Ed). 1984;289(6457):1495‐1497.

Bengtsson C, Blohme G, Lapidus L, Lissner L, Lundgren H. Diabetes incidence in users and non‐users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12‐year prospective population study of women in Gothenburg, Sweden. J Intern Med. 1992;231(6):583‐588.

Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed‐dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29(12):2592‐2597.

Smith SM, Anderson SD, Wen S, et al. Lack of correlation between thiazide‐induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009;29(10):1157‐1165.

Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191‐2201.

Dhayat NA, Faller N, Bonny O, et al. Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double‐blind placebo‐controlled trial. BMC Nephrol. 2018;19(1):349.

Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta‐analysis. Lancet. 2007;369(9557):201‐207.

Ren H, Qin L, Wang W, et al. Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. Am J Nephrol. 2013;37(2):152‐157.

Blanchard A, Vallet M, Dubourg L, et al. Resistance to insulin in patients with Gitelman syndrome and a subtle intermediate phenotype in heterozygous carriers: a cross‐sectional study. J Am Soc Nephrol. 2019;30(8):1534‐1545.

Carter BL, Einhorn PT, Brands M, et al. Thiazide‐induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008;52(1):30‐36.

Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ED. Diuretics and beta‐blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 1999;159(6):551‐558.

Savage PJ, Pressel SL, Curb JD, et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741‐751.

Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow‐up study. J Clin Endocrinol Metab. 2006;91(9):3457‐3463.

Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep. 2003;5(2):106‐109.

Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS. Thiazide‐induced hyperglycaemia: a role for calcium‐activated potassium channels? Diabetologia. 1996;39(7):861‐864.

Sandstrom PE. Inhibition by hydrochlorothiazide of insulin release and calcium influx in mouse pancreatic beta‐cells. Br J Pharmacol. 1993;110(4):1359‐1362.

Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321(13):868‐873.

Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of candesartan (MEDICA) study. Hypertension. 2008;52(6):1030‐1037.

Cooper‐DeHoff RM, Wen S, Beitelshees AL, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010;55(1):61‐68.

Harper R, Ennis CN, Sheridan B, Atkinson AB, Johnston GD, Bell PM. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309(6949):226‐230.

Rooney DP, Neely RD, Ennis CN, et al. Insulin action and hepatic glucose cycling in essential hypertension. Metabolism. 1992;41(3):317‐324.

Sener A, Jijakli H, Zahedi Asl S, et al. Possible role of carbonic anhydrase in rat pancreatic islets: enzymatic, secretory, metabolic, ionic, and electrical aspects. Am J Physiol Endocrinol Metab. 2007;292(6):E1624‐E1630.

Parkkila AK, Scarim AL, Parkkila S, Waheed A, Corbett JA, Sly WS. Expression of carbonic anhydrase V in pancreatic beta cells suggests role for mitochondrial carbonic anhydrase in insulin secretion. J Biol Chem. 1998;273(38):24620‐24623.

Boquist L, Backman AM, Stromberg C. Effects of acetazolamide on insulin release, serum glucose and insulin, glucose tolerance, and alloxan sensitivity of mice. Med Biol. 1980;58(3):169‐173.

Kucharczyk P, Albano G, Deisl C, et al. Thiazides attenuate insulin secretion through inhibition of mitochondrial carbonic anhydrase 5b in β‐islet cells in mice. J Am Soc Nephrol. 2023;34:1179‐1190. doi:10.1681/ASN.0000000000000122

Matsumoto K, Miyazaki H, Fujii T, Hashimoto M. Binding of sulfonamides to erythrocytes and their components. Chem Pharm Bull (Tokyo). 1989;37(7):1913‐1915.

Dieterle W, Wagner J, Faigle JW. Binding of chlorthalidone (Hygroton®) to blood components in man. Eur J Clin Pharmacol. 1976;10:37‐42.

Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X‐ray crystallographic studies for the indapamide‐isozyme II adduct. Bioorg Med Chem Lett. 2008;18(8):2567‐2573.

Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X‐ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009;17(3):1214‐1221.

Shah GN, Rubbelke TS, Hendin J, et al. Targeted mutagenesis of mitochondrial carbonic anhydrases VA and VB implicates both enzymes in ammonia detoxification and glucose metabolism. Proc Natl Acad Sci USA. 2013;110(18):7423‐7428.

Merrins MJ, Corkey BE, Kibbey RG, Prentki M. Metabolic cycles and signals for insulin secretion. Cell Metab. 2022;34:947‐968.

MacDonald MJ. Feasibility of a mitochondrial pyruvate malate shuttle in pancreatic islets. Further implication of cytosolic NADPH in insulin secretion. J Biol Chem. 1995;270(34):20051‐20058.

Xu J, Han J, Long YS, Epstein PN, Liu YQ. The role of pyruvate carboxylase in insulin secretion and proliferation in rat pancreatic beta cells. Diabetologia. 2008;51(11):2022‐2030.

Prentki M, Matschinsky FM, Madiraju SR. Metabolic signaling in fuel‐induced insulin secretion. Cell Metab. 2013;18(2):162‐185.

Abulizi A, Cardone RL, Stark R, et al. Multi‐tissue acceleration of the mitochondrial phosphoenolpyruvate cycle improves whole‐body metabolic health. Cell Metab. 2020;32(5):751‐766 e711.

Lewandowski SL, Cardone RL, Foster HR, et al. Pyruvate kinase controls signal strength in the insulin secretory pathway. Cell Metab. 2020;32(5):736‐750 e735.

Sehnal D, Bittrich S, Deshpande M, et al. Mol* viewer: modern web app for 3D visualization and analysis of large biomolecular structures. Nucleic Acids Res. 2021;49(W1):W431‐W437.

Cryo‐EM structure of human NCC (class 1). 2022.

Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235‐242.